Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$176.64 USD

176.64
9,476,916

+1.92 (1.10%)

Updated Aug 15, 2025 04:00 PM ET

After-Market: $177.00 +0.36 (0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (80 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

The Zacks Analyst Blog Highlights: Johnson & Johnson, SAP, McDonalds, Coca-Cola and Lockheed Martin

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Johnson & Johnson, SAP, McDonalds, Coca-Cola and Lockheed Martin

Kevin Cook headshot

Bear of the Day: Penumbra (PEN)

by Kevin Cook

Growth stalls for an innovator in blood clot removal and the deadly shadow of stroke with catheter-based aspiration technologies

Sheraz Mian headshot

Is the Earnings Improvement for Real?

by Sheraz Mian

Today's Research Daily provides an update on the Q2 earnings season, in addition to featuring new research reports on JNJ (JNJ), SAP (SAP), McDonalds (MCD) & others.

Zacks Equity Research

Biogen (BIIB) Beats on Q2 Earnings, Raises EPS View, Stock Up

by Zacks Equity Research

Biogen (BIIB) beats second-quarter estimates for both earnings and sales. Stock rises.

Zacks Equity Research

Novartis' (NVS) Q2 Earnings Surpass Estimates, Sales Miss

by Zacks Equity Research

Novartis' (NVS) second-quarter 2020 sales take a hit due to the coronavirus pandemic.

Zacks Equity Research

Lilly's Plaque Psoriasis Candidate Meets Phase III Study Goals

by Zacks Equity Research

Lilly's (LLY) autoimmune disorder candidate, mirikizumab, superior to Cosentyx in a phase III study for patients with moderate-to-severe plaque psoriasis.

Zacks Equity Research

AstraZeneca's Farxiga Gets Fast Track Tag for New Indication

by Zacks Equity Research

AstraZeneca's (AZN) Farxiga gets Fast Track status to reduce the risk of cardiovascular death or hospitalization for heart failure following a heart attack in adult patients.

Kinjel Shah headshot

Pharma Stock Roundup: J&J Q2 Earnings, FDA Approvals, Fast Track Tags & More

by Kinjel Shah

J&J (JNJ) beats Q2 estimates for earnings and sales. FDA grants fast track designation to Pfizer's (PFE) coronavirus vaccine candidates.

Kinjel Shah headshot

J&J Sets in Motion Pharma Q2 Earnings: 3 Stocks to Buy

by Kinjel Shah

Investors typically look at J&J's (JNJ) results for signals about how the rest of the big drugmakers will fare.

Zacks Equity Research

AC Immune Advances Alzheimer's Vaccine to Phase Ib/IIa Study

by Zacks Equity Research

AC Immune (ACIU) advances its Alzheimer's disease vaccine, ACI-35.030, to phase Ib/IIa study.

Zacks Equity Research

Stock Market News for Jul 17, 2020

by Zacks Equity Research

Benchmarks closed lower on Thursday, mostly dragged down by decline in tech stocks.

Zacks Equity Research

Should iShares Morningstar LargeCap Value ETF (JKF) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JKF

Mark Vickery headshot

Thursday Markets Drift Down, Netflix Q2 Mixed

by Mark Vickery

The main problem for investors in the after-market trading on Netflix's (NFLX) earnings had to do with subscription adds.

Zacks Equity Research

Economic Data Deluge

by Zacks Equity Research

Economic Data Deluge

Mark Vickery headshot

Jobless Claims Fall, Retail Sales Grow, Plus Q2 Earnings

by Mark Vickery

While Initial and Continuing Jobless Claims fell, Retail Sales and Philly Fed were up, and JNJ, MS and BAC reported good Q2 results.

Zacks Equity Research

J&J (JNJ) Beats on Q2 Earnings & Sales, Ups 2020 Guidance

by Zacks Equity Research

J&J (JNJ) beats second-quarter 2020 estimates for both earnings and sales. It increases its adjusted earnings and sales outlook for 2020.

Zacks Equity Research

Johnson & Johnson (JNJ) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 11.33% and 4.37%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Tracey Ryniec headshot

5 Earnings Charts for the Coronavirus Recovery

by Tracey Ryniec

Drug makers, restaurants, industrials and transports will tell you what is really going on in the US economy.

Zacks Equity Research

J&J's Tremfya Receives FDA Approval for Psoriatic Arthritis

by Zacks Equity Research

J&J's (JNJ) sBLA seeking approval for Tremfya for active psoriatic arthritis receives approval in the United States.

Zacks Equity Research

Moderna Rallies on Encouraging Coronavirus Vaccine Study Data

by Zacks Equity Research

Moderna's (MRNA) coronavirus vaccine candidate achieves levels of antibodies similar or higher than those typically found in a patient who recovered from COVID-19 naturally.

Zacks Equity Research

Why Earnings Season Could Be Great for Johnson & Johnson (JNJ)

by Zacks Equity Research

Johnson & Johnson (JNJ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Novavax and Johnson & Johnson

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Novavax and Johnson & Johnson

Sweta Jaiswal, FRM headshot

Biotech ETFs to Shine on Pfizer's Coronavirus Vaccine Progress

by Sweta Jaiswal, FRM

Two out of four of Pfizer's coronavirus vaccine candidates, BNT162b1 and BNT162b2, have been granted the 'fast track' designation by the FDA.

Tirthankar Chakraborty headshot

Race to Coronavirus Vaccine Heats Up: 5 Stocks in Spotlight

by Tirthankar Chakraborty

Two experimental coronavirus vaccines, manufactured jointly by Pfizer and BioNTech, have received fast track status from the FDA.

Zacks Equity Research

Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IWX